RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2021 Jan 8

PMID 33414790

Citations 38

Authors

Jonas B Sandbrink

Robin J Shattock

Affiliations

Soon will be listed here.

Abstract

The COVID-19 pandemic demonstrates the ongoing threat of pandemics caused by novel, previously unrecognized, or mutated pathogens with high transmissibility. Currently, vaccine development is too slow for vaccines to be used in the control of emerging pandemics. RNA-based vaccines might be suitable to meet this challenge. The use of an RNA-based delivery mechanism promises fast vaccine development, clinical approval, and production. The simplicity of transcription of mRNA suggests potential for fast, scalable, and low-cost manufacture. RNA vaccines are safe in theory and have shown acceptable tolerability in first clinical trials. Immunogenicity of SARS-CoV-2 mRNA vaccines in phase 1 trials looks promising, however induction of cellular immunity needs to be confirmed and optimized. Further optimization of RNA vaccine modification and formulation to this end is needed, which may also enable single injection regimens to be achievable. Self-amplifying RNA vaccines, which show high immunogenicity at low doses, might help to improve potency while keeping manufacturing costs low and speed high. With theoretical properties of RNA vaccines looking promising, their clinical efficacy is the key remaining question with regard to their suitability for tackling emerging pandemics. This question might be answered by ongoing efficacy trials of SARS-CoV-2 mRNA vaccines.

Citing Articles

Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability.

Gulati G, Simpson A, MacMillen Z, Krieger K, Sharma S, Erasmus J J Control Release. 2024; 377:81-92.

PMID: 39547422 PMC: 11663110. DOI: 10.1016/j.jconrel.2024.11.023.

A Lipid Nanoparticle-Formulated Self-Amplifying RNA Rift Valley Fever Vaccine Induces a Robust Humoral Immune Response in Mice.

Kitandwe P, Rogers P, Hu K, Nayebare O, Blakney A, McKay P Vaccines (Basel). 2024; 12(10).

PMID: 39460255 PMC: 11511412. DOI: 10.3390/vaccines12101088.

Advances in Dendritic-Cell-Based Vaccines against Respiratory Fungal Infections.

Kulkarni N, Nanjappa S Vaccines (Basel). 2024; 12(9).

PMID: 39340013 PMC: 11435842. DOI: 10.3390/vaccines12090981.

Rapidly Evolving SARS-CoV-2: A Brief Review Regarding the Variants and their Effects on Vaccine Efficacies.

Nawaz S, Janiad S, Fatima A, Saleem M, Fatima U, Ali A Infect Disord Drug Targets. 2024; 24(4):58-66.

PMID: 38178666 DOI: 10.2174/0118715265271109231129112515.

A duplex droplet digital PCR assay for absolute quantification and characterization of long self-amplifying RNA.

Casmil I, Huang C, Blakney A Sci Rep. 2023; 13(1):19050.

PMID: 37923834 PMC: 10624827. DOI: 10.1038/s41598-023-46314-6.

References

Corbett K, Edwards D, Leist S, Abiona O, Boyoglu-Barnum S, Gillespie R . SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020; 586(7830):567-571. PMC: 7581537. DOI: 10.1038/s41586-020-2622-0. View

Blakney A, McKay P, Yus B, Aldon Y, Shattock R . Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA. Gene Ther. 2019; 26(9):363-372. PMC: 6760535. DOI: 10.1038/s41434-019-0095-2. View

Feldman R, Fuhr R, Smolenov I, Ribeiro A, Panther L, Watson M . mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019; 37(25):3326-3334. DOI: 10.1016/j.vaccine.2019.04.074. View

Alberer M, Gnad-Vogt U, Hong H, Mehr K, Backert L, Finak G . Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017; 390(10101):1511-1520. DOI: 10.1016/S0140-6736(17)31665-3. View

Stitz L, Vogel A, Schnee M, Voss D, Rauch S, Mutzke T . A thermostable messenger RNA based vaccine against rabies. PLoS Negl Trop Dis. 2017; 11(12):e0006108. PMC: 5737050. DOI: 10.1371/journal.pntd.0006108. View

Bloom D, Cadarette D . Infectious Disease Threats in the Twenty-First Century: Strengthening the Global Response. Front Immunol. 2019; 10:549. PMC: 6447676. DOI: 10.3389/fimmu.2019.00549. View

Andries O, Mc Cafferty S, De Smedt S, Weiss R, Sanders N, Kitada T . N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 2015; 217:337-44. DOI: 10.1016/j.jconrel.2015.08.051. View

Kis Z, Shattock R, Shah N, Kontoravdi C . Emerging Technologies for Low-Cost, Rapid Vaccine Manufacture. Biotechnol J. 2018; 14(1):e1800376. DOI: 10.1002/biot.201800376. View

Cascio A, Bosilkovski M, Rodriguez-Morales A, Pappas G . The socio-ecology of zoonotic infections. Clin Microbiol Infect. 2010; 17(3):336-42. DOI: 10.1111/j.1469-0691.2010.03451.x. View

10.

Graham B, Corbett K . Prototype pathogen approach for pandemic preparedness: world on fire. J Clin Invest. 2020; 130(7):3348-3349. PMC: 7324162. DOI: 10.1172/JCI139601. View

11.

Chakrabarti A, Jha B, Silverman R . New insights into the role of RNase L in innate immunity. J Interferon Cytokine Res. 2010; 31(1):49-57. PMC: 3021357. DOI: 10.1089/jir.2010.0120. View

12.

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

13.

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

14.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

15.

Corbett K, Flynn B, Foulds K, Francica J, Boyoglu-Barnum S, Werner A . Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020; 383(16):1544-1555. PMC: 7449230. DOI: 10.1056/NEJMoa2024671. View

16.

Geall A, Verma A, Otten G, Shaw C, Hekele A, Banerjee K . Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A. 2012; 109(36):14604-9. PMC: 3437863. DOI: 10.1073/pnas.1209367109. View

17.

Perri S, Greer C, Thudium K, Doe B, Legg H, Liu H . An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol. 2003; 77(19):10394-403. PMC: 228391. DOI: 10.1128/jvi.77.19.10394-10403.2003. View

18.

Trombetta C, Montomoli E . Influenza immunology evaluation and correlates of protection: a focus on vaccines. Expert Rev Vaccines. 2016; 15(8):967-76. DOI: 10.1586/14760584.2016.1164046. View

19.

Thangavel R, Bouvier N . Animal models for influenza virus pathogenesis, transmission, and immunology. J Immunol Methods. 2014; 410:60-79. PMC: 4163064. DOI: 10.1016/j.jim.2014.03.023. View

20.

Lindsay K, Bhosle S, Zurla C, Beyersdorf J, Rogers K, Vanover D . Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat Biomed Eng. 2019; 3(5):371-380. DOI: 10.1038/s41551-019-0378-3. View